The coronary stent market in India has reached a crucial milestone, with a valuation of USD 843.8 million in 2023, reflecting a transformative shift in the country’s approach to cardiovascular ...

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced its financial results for 2024, alongside major ...

To accelerate potential completion of ongoing partnership restructuring negotiations, Orchestra BioMed and Terumo have elected to enter a mediation process and are currently working on a procedural ...

Investigators seeking to compare real-world outcomes with drug-eluting stents (DES) in symptomatic femoropopliteal lesions have s ...

The 1-year rate of in-stent restenosis (ISR) was 23.4% (15/64). The rate of ISR in Mori C lesions (53.8%, 7/13) was significantly higher than that in Mori A (15.8%, 3/19) or Mori B lesions (15.6%, ...

P2Y 12 inhibitor‐based single antiplatelet therapy (SAPT) after drug‐eluting stent implantation reduces major bleeding without increasing the risk of major adverse cardiovascular and cerebral events ...

WASHINGTON, DC—A newly approved drug-coated balloon (DCB) for the treatment of in-stent restenosis (ISR) continues to be safe and effective, with fewer events and repeat interventions compared with ...

That included 61% patients with acute coronary syndrome, 31.8% with diabetes, 55.3% with complex lesions, 22.8% with bifurcation lesions and 28% in-stent restenosis (ISR). Outcomes included all ...

Background Intracranial atherosclerotic stenosis (ICAS) represents a major cause of ischemic stroke, with endovascular treatments, such as stenting, facing challenges such as restenosis and ...

Although drug-eluting stents (DES) are more effective than bare-metal stent (BMS) in reducing restenosis rate, there is the need for a prolonged dual antiplatelet therapy. Furthermore, concerns ...